What 2025 means for the life sciences sector in the New Year. If I had to describe 2025 in one phrase, it would be this: a year of two halves, held together by uncertainty.

Since TrumpRx was announced in 2025, 16 Big Pharma companies have agreed to sell their drugs via the platform, including ...

Within the context of “The Great Repricing,” this distinction matters. The pressure on the commercial channel is not coming ...

In reality, program design covers everything from offer amount and caps to eligibility rules and channel mix, yet many ...

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides ...

This year brings several major healthcare policy changes for patients. While some of these changes improve healthcare access and affordability, two key decisions could have a detrimental impact on ...

1. FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients. United States Federal ...

The combination of GENEROUS for Medicaid, Globe for Medicare Part B and Guard for Medicare Part D will heavily impact the US drug market. President Trump’s rhetoric has been that other countries ...

Roth began by sharing what he believes to be the single-most important characteristic of pharma company long-term survival ...

In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, ...

By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to ...

In the final part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, outlines how real-time AI signal sharing across supply chain partners can help pharma ...